Demographic, disease characteristics and treatments in patients with PsA stratified by gender
| Total PsA n=1033 | Male n=501 (48.5) | Female n=532 (51.5) | P value | Standardised difference | |
| Age at study visit | 51.8 (13.0) | 52.3 (13.3) | 51.3 (12.7) | <0.05 | 0.077 |
| Smoking habit (ever) | 494 (47.9) | 278 (55.6) | 216 (40.6) | <0.001 | 0.304 |
| Alcohol (ever) | 451 (43.7) | 315 (63.0) | 136 (25.6) | <0.001 | 0.813 |
| Body mass index (kg/m2) | 28.0 (5.9) | 27.3 (4.6) | 28.7 (6.8) | <0.001 | −0.241 |
| University education | 320 (31.0) | 177 (35.4) | 143 (26.9) | <0.01 | 0.184 |
| Family history of SpA | 375 (36.3) | 159 (31.7) | 216 (40.6) | <0.01 | −0.186 |
| Family history of PsO | 341 (36.1) | 142 (30.7) | 199 (41.2) | <0.01 | −0.22 |
| Diagnosis delay (years) since the first symptom | 9.1 (11.1) | 9.1 (11.0) | 9.0 (11.2) | 0.87 | 0.009 |
| Symptom duration | 16.8 (12.3) | 17.3 (12.1) | 16.2 (12.4) | 0.15 | 0.09 |
| Axial involvement according to the rheumatologist | 367 (35.5) | 196 (39.1) | 171 (32.1) | 0.02 | 0.147 |
| Inflammatory back pain (ASAS criteria) | 366 (35.4) | 188 (37.5) | 178 (33.5) | 0.30 | 0.084 |
| Sacroiliitis on imaging, n/N (%) by: | |||||
| xRay mNY criteria | 212/855 (24.8) | 115/417 (27.6) | 97/438 (22.1) | 0.07 | 0.128 |
| MRI-SIJ, ASAS def | 150/589 (25.5) | 72/294 (24.5) | 78/295 (26.4) | 0.59 | −0.044 |
| mNY criteria or ASAS def | 273/877 (31.1) | 141/431 (32.7) | 132/446 (29.6) | 0.34 | 0.067 |
| HLA-B27 positive | 86/474 (18.1) | 49/234 (20.9) | 37/240 (15.4) | 0.26 | 0.143 |
| Elevated CRP (>5 mg/L) | 584 (58.8) | 281 (58.5) | 303 (59.1) | 0.87 | −0.012 |
| CRP (mg/L) | 11.4 (28.6) | 11.7 (33.3) | 11.2 (23.4) | 0.81 | 0.017 |
| Peripheral arthritis | 938 (90.8) | 456 (91.0) | 482 (90.6) | 0.82 | 0.014 |
| Enthesitis | 473 (45.8) | 212 (42.3) | 261 (49.1) | <0.05 | −0.137 |
| Dactylitis | 382 (37.0) | 190 (37.9) | 192 (36.1) | 0.54 | 0.037 |
| Psoriasis | 946 (91.6) | 466 (93.0) | 480 (90.2) | 0.11 | 0.101 |
| IBD | 6 (0.6) | 3 (0.6) | 3 (0.6) | 0.94 | 0 |
| Uveitis | 27 (2.6) | 11 (2.2) | 16 (3.0) | 0.41 | −0.05 |
| Fibromyalgia according to: | |||||
| Treating rheumatologist | 120 (11.6) | 17 (3.4) | 103 (19.4) | <0.001 | −0.52 |
| FiRST questionnaire | 245 (24.9) | 73 (15.1) | 172 (34.4) | <0.001 | −0.459 |
| csDMARD (ever) | 959 (92.8) | 465 (92.8) | 494 (92.9) | 0.98 | −0.004 |
| bDMARD (ever) | 668 (64.7) | 331 (66.1) | 337 (63.3) | 0.36 | 0.059 |
Results are shown as absolute numbers (percentages). Estimates with p<0.05 are highlighted in bold. Standardised difference scores of 0.2, 0.5 and 0.8 represent small, medium and large effect sizes, respectively.
ASAS, Assessment of SpondyloArthritis International Society; bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FiRST, Fibromyalgia Rapid Screening Tool; IBD, inflammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis.